MARKET

AGIO

AGIO

Agios Pharmaceuticals Inc
NASDAQ
45.23
+0.01
+0.02%
After Hours: 45.23 0 0.00% 16:20 06/24 EDT
OPEN
45.62
PREV CLOSE
45.22
HIGH
46.34
LOW
45.05
VOLUME
482.49K
TURNOVER
0
52 WEEK HIGH
49.06
52 WEEK LOW
19.80
MARKET CAP
2.57B
P/E (TTM)
-7.1731
1D
5D
1M
3M
1Y
5Y
Agios Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 11h ago
Weekly Report: what happened at AGIO last week (0617-0621)?
Weekly Report · 22h ago
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
NASDAQ · 23h ago
Agios Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 06/17 23:51
Expert Ratings For Agios Pharmaceuticals
Agios Pharmaceuticals has been analyzed by 4 analysts in the last three months. The biopharmaceutical company is developing treatments for cancer and rare genetic disorders of metabolism. The company has an average price target of $46.25 with a 12-month growth rate of 46.0%. The company's market capitalization is above the industry average.
Benzinga · 06/17 14:01
Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticals
Benzinga · 06/17 13:31
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Agios Pharma (AGIO) and Viking Therapeutics (VKTX)
TipRanks · 06/17 11:32
Piper Sandler Keeps Their Buy Rating on Agios Pharma (AGIO)
TipRanks · 06/17 10:41
More
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

Webull offers Agios Pharmaceuticals Inc stock information, including NASDAQ: AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.